Literature DB >> 9860406

Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C.

S Sugano1, T Suzuki, M Watanabe, K Ohe, K Ishii, T Okajima.   

Abstract

OBJECTIVE: The pathogenesis of retinal complications, such as retinal hemorrhage and cotton-wool spots formation, during interferon (IFN) therapy is unclear. We studied the relationship between the presence of retinal complications and levels of plasma-activated complement 5 (C5a), a known potent intravascular aggregator of granulocytes, during IFN-alpha therapy.
METHODS: Forty-five patients with chronic hepatitis C but without diabetes mellitus and hypertension were studied. IFN-alpha was used 10 MU per day for 2 wk and 3 times weekly for an additional 22 wk. In 25 patients with IFN therapy, the optic fundi were examined before therapy began, every 4 wk thereafter, and whenever patients complained of visual symptoms. C5a levels were measured before, and during the 4th, 8th, 12th, and 24th wk, and at any time that a retinal complication was discovered. Twenty patients served as IFN-untreated controls. They had six optic fundi examinations, each 4 wk apart. C5a levels were measured three times, 4 wk apart, in 10 controls.
RESULTS: No retinal hemorrhage or cotton-wool spots were detected before IFN-alpha therapy or in any of the controls. However, retinal hemorrhage occurred in six patients (24%) during IFN-alpha therapy. Five of six episodes occurred within the first 8 wk. Only three patients with retinal hemorrhage had visual symptoms. Cotton-wool spots developed in four patients with retinal hemorrhage. Retinal hemorrhage and cotton-wool spots resolved gradually despite continuous administration of IFN-alpha. Before IFN therapy and in controls, all C5a levels were <7 ng/ml. When retinal hemorrhage occurred, C5a was significantly increased (27.3+/-15.6 ng/ml,p < 0.01) relative to levels from the same patients before and after the hemorrhage (5.7+/-1.1 ng/ml), and also relative to levels in IFN-a-treated patients without retinal hemorrhage (5.7+/-1.1 ng/ml) and compared with levels in IFN-untreated controls (5.4+/-0.7 ng/ml).
CONCLUSIONS: Retinal hemorrhage or cotton-wool spots often occur during IFN-alpha therapy for chronic hepatitis C. This study suggests that a high C5a level may be an important step in the pathogenesis of retinal capillary infarction, hemorrhage, and cotton-wool spots formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9860406     DOI: 10.1111/j.1572-0241.1998.00701.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  16 in total

1.  [Anterior ischemic optic neuropathy and retinopathy during systemic interferon therapy].

Authors:  M Moerchen; A-K Rowton; K-H Emmerich
Journal:  Ophthalmologe       Date:  2007-08       Impact factor: 1.059

Review 2.  Ophthalmologic complications of antiviral therapy in hepatitis C treatment.

Authors:  Roderick O'Day; Mark C Gillies; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

3.  Pegylated interferon alpha-associated optic neuropathy.

Authors:  Kathleen T Berg; Bruce Nelson; Andrew R Harrison; Linda K McLoon; Michael S Lee
Journal:  J Neuroophthalmol       Date:  2010-06       Impact factor: 3.042

4.  Branch retinal vein thrombosis and visual loss probably associated with pegylated interferon therapy of chronic hepatitis C.

Authors:  Luciana Lofego Goncalves; Alberto Queiroz Farias; Patrícia Lofego Gonçalves; Elbio-Antonio D'Amico; Flair José Carrilho
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

5.  Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  Chiaki Okuse; Hiroshi Yotsuyanagi; Yoshihiko Nagase; Yuhtaro Kobayashi; Kiyomi Yasuda; Kazuhiko Koike; Shiro Iino; Michihiro Suzuki; Fumio Itoh
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

Review 6.  Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.

Authors:  V Peponis; V C Kyttaris; S E Chalkiadakis; S Bonovas; N M Sitaras
Journal:  Lupus       Date:  2010-02-09       Impact factor: 2.911

7.  [Combined retinal artery and vein occlusions associated with interferon beta therapy].

Authors:  T Jenisch; T Dietrich-Ntoukas; A B Renner; H Helbig; M A Gamulescu
Journal:  Ophthalmologe       Date:  2012-01       Impact factor: 1.059

Review 8.  Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C.

Authors:  Ji-Hua Xue; Hai-Hong Zhu; Jing Wang; Zhi Chen
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

9.  A case of deep venous thrombosis associated with pegylated interferon alpha2b plus ribavirin treatment of chronic hepatitis C.

Authors:  Chiaki Okuse; Kayo Adachi; Yoshiki Katakura; Kotaro Matsunaga; Toshiya Ishii; Nobuyuki Matsumoto; Hiroshi Yotsuyanagi; Shiro Iino; Michihiro Suzuki; Fumio Itoh
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

Review 10.  Drug-induced thrombosis: an update.

Authors:  Yuval Ramot; Abraham Nyska; Galia Spectre
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.